Log In
Print this Print this

RORgamma agonist (LYC-55716)

  Manage Alerts
Collapse Summary General Information
Company Lycera Corp.
DescriptionOral selective RAR-related orphan receptor C (RORC; RORgamma) agonist that enhances effector function of T helper 17 cells and attenuates immunosuppressive mechanisms
Molecular Target RAR-related orphan receptor C (RORC) (RORgamma)
Mechanism of ActionRAR-related orphan receptor (ROR) agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationSolid tumors
Indication DetailsTreat advanced, relapsed or refractory solid tumors; Treat solid tumors
Regulatory Designation
PartnerCelgene Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today